We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...

SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

Abbott today announced positive early results from a study evaluating its investigational Amulet 360 left atrial appendage ...

A head-to-head, randomized study of the two leading heart implants worldwide for reducing the risk of stroke among people with an irregular pulse found there was little difference between their safety ...

The 45-day post-implantation results support use of a next-generation device in people with atrial fibrillation, but caution is advised until longer-term results are available.

Three years after the U.S. FDA approval of Abbott Laboratories’ Amplatzer Amulet, results of its investigational device exemption trial failed to notably differentiate Abbott’s left atrial appendage ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

TCT 489: The Comparison of Tissue Characteristics of Restenosis After Coronary Interventions: Insights From a Histological Analysis After Directional Coronary Atherectomy Receive the the latest news, ...

Boston Scientific and Abbott this week both put forward separate studies supporting their respective implants for sealing off the heart’s left atrial appendage—the pocket within the cardiac muscle ...

First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...